Optimizing Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Malignancies
优化造血干细胞移植治疗血液恶性肿瘤
基本信息
- 批准号:10596338
- 负责人:
- 金额:$ 20.49万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-09-07 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:Acute Myelocytic LeukemiaAllogenicAnti-CD47AntibodiesAntibody-drug conjugatesBasic ScienceCellular immunotherapyChimerismClinical PathologyDevelopment PlansDoctor of MedicineDoctor of PhilosophyDonor Lymphocyte InfusionEngraftmentEnvironmentExtramural ActivitiesFundingGoalsGrowthHematologic NeoplasmsHematological DiseaseHematopoiesisHematopoietic Stem Cell TransplantationHospitalsImmunologyImmunotherapyInjuryJAK1 geneLeukemic CellLifeLymphomaMalignant - descriptorMediatingMedicineMentorsMethodsModelingMusMyelogenousOncologyPTPRC genePhysiciansPublishingRegimenResearchResidenciesResourcesSavingsScientistTimeToxicity due to chemotherapyTrainingTraining ProgramsTransplant RecipientsTransplantation ConditioningUniversitiesWashingtonbasecareercareer developmentconditioningexperimental studyfollower of religion Jewishgraft vs host diseasegraft vs leukemia effectinhibitorirradiationmedical schoolsnovelnovel strategiespost-transplantprogramsresearch and developmentresponsesystemic toxicitytranslational potentialtransplantation therapy
项目摘要
Project Summary/Abstract
This NCI Diversity Supplement application outlines the research and career development plans for
Stephen Persaud, M.D., Ph.D, who is preparing for a career as an academic physician-scientist. Dr. Persaud
completed his M.D. and PhD in immunology in 2015 at Washington University School of Medicine, then
completed his residency in Clinical Pathology in 2018 at Barnes-Jewish Hospital as part of the Physician
Scientist Training Program. During his residency elective time, he began his postdoctoral research in the lab of
John DiPersio, M.D., Ph.D, Chief of the Oncology Division in the Department of Medicine at Washington
University School of Medicine. Dr. DiPersio is an expert in allogeneic hematopoietic stem cell transplantation
(allo-HSCT), normal and malignant hematopoiesis, and cellular immunotherapy, and has an outstanding track
record of training successful physician-scientists. The scientific resources and environment provided by the
DiPersio lab and Washington University School of Medicine, combined with the mentoring, educational, and
training plans described herein, will propel Dr. Persaud’s career forward by enhancing the growth of his
independent research program and his competitiveness for extramural funding.
The long-term goal of the proposed research is to optimize minimally toxic, antibody-based
HSCT conditioning regimens for the therapy of acute myeloid leukemia (AML). Led by Dr. Persaud, the
DiPersio lab published the first study showing that CD45- or cKit-targeted antibody-drug conjugates (ADCs)
combined with Janus kinase 1/2 (JAK1/2) inhibitors enabled fully MHC-mismatched HSCT in mice, with
myeloid donor chimerism ≥99%. Notably, unlike conditioning with irradiation, ADC-based conditioning did not
promote graft-versus-host disease (GvHD). Finally, JAK1/2 inhibitors plus CD45-ADC balanced GvHD with
GvL activity in a delayed donor lymphocyte infusion lymphoma model, with evidence of direct ADC-mediated
antitumor efficacy. By enabling allogeneic engraftment and GvL effects while mitigating GvHD and systemic
toxicities, our novel regimen provides the ideal blend of activities for the immediate post-transplant period in
the treatment of AML. We will build on this body of work with two Specific Aims. In Aim 1, we will develop and
characterize fully myeloablative CD45 and cKit ADCs and evaluate their antileukemic efficacy and impact on
GvHD and GvL responses. In Aim 2, we will develop toxic payload-free, antibody-based conditioning methods
by combining anti-cKit and anti-CD47 targeting with JAK1/2 inhibition, which we hypothesize will
simultaneously condition for allo-HSCT and eliminate leukemia cells. Collectively, these studies will adapt
antibody-based conditioning strategies for the purpose of treating hematologic malignancies, achieving
maximal antileukemia benefit with minimal injury to the host.
项目总结/摘要
这个NCI多样性补充申请概述了研究和职业发展计划,
Stephen Persaud,医学博士,博士,谁是准备作为一个学术物理学家科学家的职业生涯。佩尔绍德博士
完成了医学博士学位2015年在华盛顿大学医学院获得免疫学博士学位,
2018年在Barnes-Jewish医院完成了临床病理学的住院医师实习,
科学家培训计划。在他的住院医生选修时间,他开始了他的博士后研究在实验室,
John DiPersio,医学博士,博士,华盛顿医学系肿瘤科主任
大学医学院。DiPersio博士是异基因造血干细胞移植专家
(allo-HSCT),正常和恶性造血,以及细胞免疫治疗,并具有出色的跟踪
培养成功的医学科学家的记录。科学资源和环境的提供
DiPersio实验室和华盛顿大学医学院,结合指导,教育,
本文所述的培训计划,将推动博士Persaud的职业生涯向前发展,提高他的成长,
独立的研究项目和他对校外资金的竞争力。
拟议研究的长期目标是优化毒性最小、基于抗体的
HSCT预处理方案治疗急性髓细胞白血病(AML)。在Persaud博士的带领下,
DiPersio实验室发表的第一项研究表明,CD 45或cKit靶向抗体-药物缀合物(ADC)
联合Janus激酶1/2(JAK 1/2)抑制剂使小鼠中完全MHC错配的HSCT成为可能,
髓系供体嵌合率≥ 99%。值得注意的是,与照射条件处理不同,基于ADC的条件处理不
促进移植物抗宿主病(GvHD)。最后,JAK 1/2抑制剂加CD 45-ADC平衡GvHD,
延迟供体淋巴细胞输注淋巴瘤模型中的GvL活性,有直接ADC介导的证据
抗肿瘤功效通过实现同种异体移植和GvL效应,同时减轻GvHD和全身性免疫缺陷,
毒性,我们的新方案提供了理想的混合活动,为立即移植后时期,
AML的治疗。我们将以这一工作为基础,有两个具体目标。在目标1中,我们将开发并
表征完全清髓性CD 45和cKit ADC,并评价其抗白血病疗效和对
GvHD和GvL应答。在目标2中,我们将开发无毒性有效载荷、基于抗体的调理方法
通过结合抗cKit和抗CD 47靶向与JAK 1/2抑制,我们假设这将
同时进行allo-HSCT条件化和清除白血病细胞。总的来说,这些研究将适应
基于抗体的调节策略,用于治疗血液恶性肿瘤,
最大的抗白血病益处,对宿主的损伤最小。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
John F. Dipersio其他文献
John F. Dipersio的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('John F. Dipersio', 18)}}的其他基金
Project 6- Targeting AML using bispecific and antibody drug conjugates
项目 6 - 使用双特异性和抗体药物偶联物靶向 AML
- 批准号:
10615336 - 财政年份:2021
- 资助金额:
$ 20.49万 - 项目类别:
Optimizing Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Malignancies
优化造血干细胞移植治疗血液恶性肿瘤
- 批准号:
10469493 - 财政年份:2017
- 资助金额:
$ 20.49万 - 项目类别:
Pilot Projects and Trans-Network Activities Core
试点项目和跨网络活动核心
- 批准号:
9446709 - 财政年份:2017
- 资助金额:
$ 20.49万 - 项目类别:
Optimizing Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Malignancies
优化造血干细胞移植治疗血液恶性肿瘤
- 批准号:
10001462 - 财政年份:2017
- 资助金额:
$ 20.49万 - 项目类别:
Optimizing Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Malignancies
优化造血干细胞移植治疗血液恶性肿瘤
- 批准号:
9765193 - 财政年份:2017
- 资助金额:
$ 20.49万 - 项目类别:
Optimizing Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Malignancies
优化造血干细胞移植治疗血液恶性肿瘤
- 批准号:
10738323 - 财政年份:2017
- 资助金额:
$ 20.49万 - 项目类别:
Optimizing Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Malignancies
优化造血干细胞移植治疗血液恶性肿瘤
- 批准号:
10246817 - 财政年份:2017
- 资助金额:
$ 20.49万 - 项目类别:
相似海外基金
HLA-homozygous iPSC-cardiomyocytE Aggregate manufacturing technoLogies for allogenic cell therapy to the heart (HEAL)
HLA-纯合 iPSC-心肌细胞 用于心脏同种异体细胞治疗 (HEAL) 的聚集体制造技术
- 批准号:
10039902 - 财政年份:2022
- 资助金额:
$ 20.49万 - 项目类别:
EU-Funded
Evaluation of the efficacy of LAT1 inhibitor to tumor stroma and immunity in an allogenic mouse model of colon cancer having abundant stroma.
在具有丰富基质的同种异体结肠癌小鼠模型中评估 LAT1 抑制剂对肿瘤基质和免疫的功效。
- 批准号:
21K15925 - 财政年份:2021
- 资助金额:
$ 20.49万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mechanism of kidney injury associated with graft-versus-host disease after allogenic stem cell transplantation
同种异体干细胞移植后移植物抗宿主病相关肾损伤的机制
- 批准号:
21K08410 - 财政年份:2021
- 资助金额:
$ 20.49万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Clarification of the origin and maintenance mechanisms of junctional epithelium and identification of its stem cells using allogenic tooth germ transplantation
阐明交界上皮的起源和维持机制并利用同种异体牙胚移植鉴定其干细胞
- 批准号:
20K21672 - 财政年份:2020
- 资助金额:
$ 20.49万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
The study about the allogenic MSCs transplantation to the cardiac disease models.
同种异体间充质干细胞移植至心脏病模型的研究。
- 批准号:
18K16395 - 财政年份:2018
- 资助金额:
$ 20.49万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Artificial nerves containing allogenic basal lamellae scaffold and bone marrow derived stem cells
含有同种异体基底板层支架和骨髓干细胞的人工神经
- 批准号:
17K10951 - 财政年份:2017
- 资助金额:
$ 20.49万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Role of HSP90-alpha in preserving immunoprivilege of allogenic mesenchymal stem cells in the ischemic heart
HSP90-α 在保护缺血心脏同种异体间充质干细胞免疫特权中的作用
- 批准号:
370541 - 财政年份:2017
- 资助金额:
$ 20.49万 - 项目类别:
Operating Grants
Attempt to Prefabricate Vascularized Allogenic Bone in Recipient -Use of Cultured Bone Marrow Cells-
尝试在受者体内预制血管化的同种异体骨 - 使用培养的骨髓细胞 -
- 批准号:
16K10863 - 财政年份:2016
- 资助金额:
$ 20.49万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Allogenic micobiota-reconstitution (AMR) for the treatment of patients with diarhea-predominant irritable bowel syndrome (IBS-D) - the AMIRA trial
同种异体微生物群重建 (AMR) 用于治疗腹泻型肠易激综合征 (IBS-D) 患者 - AMIRA 试验
- 批准号:
276706135 - 财政年份:2015
- 资助金额:
$ 20.49万 - 项目类别:
Clinical Trials
Induction of thyme epithelial cells from iPS cells and application to allogenic transplantation
iPS细胞诱导百里香上皮细胞及其在同种异体移植中的应用
- 批准号:
15H04915 - 财政年份:2015
- 资助金额:
$ 20.49万 - 项目类别:
Grant-in-Aid for Scientific Research (B)